Skip to main content

 

Antibiotics are not linked to Autoimmune disease in kids

EurekAlert!

The global incidence of autoimmune diseases among children has increased over the past few decades.

Teaching You How to Think… (8.15.2025)

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and  aphorisms to live by.

The Patient Journey with Rheumatic Disease

Oton and colleagues have reviewed the "patient journey" - from symptoms to specialty referral in those diagnosed with rheumatic and musculoskeletal diseases (RMDs).

A New RA Approval (8.1.2025)

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors

Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.

NHANES, Numbers, & Risk (7.18.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".

1 in 5 Patients are Unaware of their Arthritis Diagnosis

Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA.  Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

This article was originally published June 12, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy! 

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment.

MTX Fails Knee OA (6.6.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Diagnosing Neuropsychiatric SLE (5.23.2025)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

Hydroxychloroquine for Everyone

Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage.

Social

Rheumatic Dz & HIV - Arthralgia: self limiting - HIV-assoc arthritis: mimics RA - Occurs w/ HIV: SpA, ReA, PsA - Less : IIM, vasculitis, opportunistic infxn https://t.co/Yf7jZ0icZw https://t.co/6FuJgvDYRF
Dr. John Cush @RheumNow ( View Tweet )
5 days 8 hours ago
Systemic immune-inflammation index (SII), as a potential biomarker -- computed as platelet count × neutrophil count/lymphocyte count. SII has been shown to be useful in RA, PsA, SpA, SLE and vasculitis, reflecting disease activity, drug responses & supplements ESR & CRP levels https://t.co/LuFaYbWiWN
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 6 days ago
Rheums! Question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. https://t.co/HsqM9xLNtP https://t.co/voONsOLeSK
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Lichenoid rash vs SCLE? JAMA Dermatology case - 60yoM w/ https://t.co/xl11CwB1AJ problems & meds has pink-red papules (central hypopigmentation) on arms, chest, back (no fungus). Bx= lichenoid dermatitis. Rash worsened, red & annular; Dx now SCLE +ANA/Ro/La) from diltiazem. SCLE

Dr. John Cush @RheumNow ( View Tweet )

1 month 4 weeks ago
Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/C4Pro6b0Jw
Dr. John Cush @RheumNow ( View Tweet )
2 months ago
EULAR 2025 – Day 2 Report Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options https://t.co/rys0pA6D6j
Dr. John Cush @RheumNow ( View Tweet )
2 months 1 week ago
Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )

2 months 1 week ago
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 @RheumNow LB0007

Aurelie Najm @AurelieRheumo ( View Tweet )

2 months 1 week ago
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. @RheumNow #EULAR2025 #LB0004

Mrinalini Dey @DrMiniDey ( View Tweet )

2 months 1 week ago
#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 1 week ago
×